The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes
Open accessAbstract
BACKGROUND: We investigated whether intensive glycemic control, combination therapy for dyslipidemia, and intensive blood-pressure control would limit the progression of diabetic retinopathy in persons with type 2 diabetes. Previous data suggest that these systemic factors may be important in the development and progression of diabetic retinopathy. METHODS: In a randomized trial, we enrolled 10,251 participants with type 2 diabetes who were at high risk for cardiovascular disease to receive either intensive or standard treatment for glycemia (target glycated hemoglobin level, <6.0% or 7.0 to 7.9%, respectively) and also for dyslipidemia (160 mg daily of fenofibrate plus simvastatin or placebo plus simvastatin) or for systolic blood-pressure control (target, <120 or <140 mm Hg). A subgroup of 2856 participants was evaluated for the effects of these interventions at 4 years on the progression of diabetic retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study Severity Scale (as assessed from seven-field stereoscopic fundus photographs, with 17 possible steps and a higher number of steps indicating greater severity) or the development of diabetic retinopathy necessitating laser photocoagulation or vitrectomy. RESULTS: At 4 years, the rates of progression of diabetic retinopathy were 7.3% with intensive glycemia treatment, versus 10.4% with standard therapy (adjusted odds ratio, 0.67; 95% confidence interval [CI], 0.51 to 0.87; P=0.003); 6.5% with fenofibrate for intensive dyslipidemia therapy, versus 10.2% with placebo (adjusted odds ratio, 0.60; 95% CI, 0.42 to 0.87; P=0.006); and 10.4% with intensive blood-pressure therapy, versus 8.8% with standard therapy (adjusted odds ratio, 1.23; 95% CI, 0.84 to 1.79; P=0.29). CONCLUSIONS: Intensive glycemic control and intensive combination treatment of dyslipidemia, but not intensive blood-pressure control, reduced the rate of progression of diabetic retinopathy. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov numbers, NCT00000620 for the ACCORD study and NCT00542178 for the ACCORD Eye study.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary composite major CV outcomes (nonfatal MI, nonfatal stroke or death from CV causes) were not reduced significantly in ACCORD (hazard ratio [HR] 0.90, p=0.16).”
From Targets for Glycemic Control (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with type 2 diabetes, an A1C ≤6.5% may be targeted to reduce the risk of CKD [Grade A, Level 1A (23)] and retinopathy [Grade A, Level 1A (21)], if they are assessed to be at low risk of hypoglycemia based on class of antihyperglycemic medication(s) utilized and the person's characteristics [Grade D, Consensus].”
From Targets for Glycemic Control (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The UK Prospective Diabetes Study randomly assigned 4209 patients with newly diagnosed type 2 diabetes to receive conventional (primarily diet) vs intensive (insulin, sulfonylurea, or, if overweight, metformin) treatment, with mean attained HbA1C of 7.9% vs 7.0%, respectively.36,37”
From Diagnosis and Treatment of Type 2 Diabetes in Adults (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Other options that can stabilize retinopathy include lifestyle intervention or bariatric surgery in persons with T2D or physical activity in persons with T1D.524–527”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [527]
Experimental — accuracy not yet measuredIn the citing paper
“Fenofibrate reduces the progression of diabetic retinopathy.413,414”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [414]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Self-citationStearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 4,803
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,023
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Self-citation
Flagged first, then by citations
Research works printed but not linked: 4
- Davis MD, 1998, Invest Ophthalmol Vis Sci, 39, 233
- Cullen JF, 1964, Trans Ophthalmol Soc U K, 84, 281
- The ACCORD Study Group, 2007, Am J Cardiol, 99, 21i
- Ismail-Beigi F, 2010, Lancet, 375, 26
Cited by
Sorted by citations
Items 601–700 of 1,000
Impact of metabolic control on macular thickness in diabetic macular oedema
Peng, Y., & Tsai, M. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164117746023 · Cited by 18
Molecular mechanisms of retinal ischemia
Fortmann, S. D., & Grant, M. B. (2018) · Current Opinion in Physiology · doi:10.1016/j.cophys.2018.12.008 · Cited by 20
LDL-Cholesterol versus Glucose in Microvascular and Macrovascular Disease
Emanuelsson, F., & Benn, M. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa242 · Cited by 18
Enright, J. M., Zhang, S., Thebeau, C. N., Siebert, E., Jin, A., Gadiraju, V., Zhang, X., Chen, S., Semenkovich, C. F., & Rajagopal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010126 · Cited by 18
Lee, D., Tomita, Y., Miwa, Y., Jeong, H., Mori, K., Tsubota, K., & Kurihara, T. (2021) · Pharmaceuticals · doi:10.3390/ph14030223 · Cited by 18
McKay, A. J., Gunn, L. H., Sathish, T., Vamos, E. P., Nugawela, M. D., Majeed, A., Molina, G., & Sivaprasad, S. (2021) · BMC Medicine · doi:10.1186/s12916-021-01966-x · Cited by 19
Association between Sickle Cell Trait and the Prevalence and Severity of Diabetic Retinopathy
Harbi, M. A., Khandekar, R. B., Kozak, I., & Schatz, P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159215 · Cited by 18
Feingold, K. R. (2017) · Europe PMC (PubMed Central) · Cited by 18
Liang, Y., Zhang, X., Mei, W., Li, Y., Du, Z., Wang, Y., Huang, Y., Zeng, X., Lai, C., Wang, S., et al. (2024) · Journal of Global Health · doi:10.7189/jogh.14.04192 · Cited by 21
Blood pressure lowering in patients with diabetes—one level might not fit all
Cooper‐DeHoff, R. M., Egelund, E. F., & Pepine, C. J. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.182 · Cited by 17
Dou, X., Nath, D., Shin, H. Y., Nurmemmedov, E., Bourne, P. C., Ma, J., & Duerfeldt, A. S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01189 · Cited by 16
Risk factors for retinopathy in hemodialysis patients with type 2 diabetes mellitus
Müller, M., Schönfeld, C., Grammer, T. B., Krane, V., Drechsler, C., Genser, B., Kohnen, T., Wanner, C., & März, W. (2020) · Scientific Reports · doi:10.1038/s41598-020-70998-9 · Cited by 18
Park, S. J., & Park, D. H. (2020) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2020.9.3.406 · Cited by 19
Tsujimoto, T., & Kajio, H. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.07.031 · Cited by 18
Atherogenic Dyslipidemia and Combination Pharmacotherapy in Diabetes: Recent Clinical Trials
Hamilton, S. J., & Watts, G. F. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.191 · Cited by 16
Rydén, L., estable, G. D. T. D. L. S. E. D. C. S. D. Y. T. D. L. C. I., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H. P., et al. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.10.015 · Cited by 20
International Diabetes Center Treatment of Type 2 Diabetes Glucose Algorithm
Simonson, G., Cuddihy, R. M., Reader, D., & Bergenstal, R. M. (2011) · Diabetes Management · doi:10.2217/dmt.10.22 · Cited by 17
Improved Outcome after Primary Vitrectomy in Diabetic Patients Treated with Statins
Tuuminen, R., Sahanne, S., Haukka, J. K., & Loukovaara, S. (2015) · European Journal of Ophthalmology · doi:10.5301/ejo.5000657 · Cited by 17
Wang, N., Zhang, C., Xu, Y., Li, S., Tan, H., Xia, W. Q., & Feng, Y. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0396-5 · Cited by 17
Cytochrome P450-epoxygenated fatty acids inhibit Müller glial inflammation
Ontko, C. D., Capozzi, M. E., Kim, M. J., McCollum, G. W., & Penn, J. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-89000-1 · Cited by 17
What can we learn from the recent blood glucose lowering megatrials?
Chan, J. C. N. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00063.x · Cited by 16
Shi, R., Zhao, L. Q., & Qi, Y. (2018) · BMC Ophthalmology · doi:10.1186/s12886-018-0769-3 · Cited by 17
Yanoff, M., & Cameron, D. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00431-0 · Cited by 18
Pharmacologic Therapy for Diabetic Retinopathy
Gardlík, R., & Fusekova, I. (2014) · Seminars in Ophthalmology · doi:10.3109/08820538.2013.859280 · Cited by 18
Sabeti, F., Carle, C. F., Nolan, C. J., Jenkins, A. J., James, A. C., Baker, L., Coombes, C., Cheung, V., Chiou, M., & Maddess, T. (2022) · BMC Ophthalmology · doi:10.1186/s12886-022-02382-2 · Cited by 18
Early diabetic eye damage: Comparing detection methods using diagnostic power
Rai, B. B., van Kleef, J., Sabeti, F., Vlieger, R., Suominen, H., & Maddess, T. (2023) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2023.09.002 · Cited by 18
Association Between Cardiovascular Health and Retinopathy in US Adults: From NHANES 2005-2008
Liu, X., Chang, Y., Li, Y., Liu, Y., Chen, N., & Cui, J. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.05.019 · Cited by 16
Lessons from PROMINENT and prospects for pemafibrate
Fruchart, J.-C., Fruchart-Najib, J., Yamashita, S., Libby, P., Yokote, K., Kodama, T., Tomita, Y., Ridker, P. M., Hermans, M. P., & Zambon, A. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02305-z · Cited by 16
Updates on medical and surgical managements of diabetic retinopathy and maculopathy
Chen, Y., Radke, N. V., Amarasekera, S., Park, D. H., Chen, N., Chhablani, J. K., Wang, N., Wu, W., Ng, D. S., Bhende, P., et al. (2025) · Asia-Pacific Journal of Ophthalmology · doi:10.1016/j.apjo.2025.100180 · Cited by 17
Czupryniak, L., Joshi, S., Gogtay, J. A., & Lopez, M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1195811 · Cited by 16
SPPARM alpha: the Lazarus effect
Fruchart, J., & Santos, R. D. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000640 · Cited by 17
Stem Cell Therapies in the Management of Diabetic Retinopathy
Megaw, R. D., & Dhillon, B. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0498-9 · Cited by 16
Statin Combination Therapy and Cardiovascular Risk Reduction
Toth, P. P., Farnier, M., Tomassini, J. E., Foody, J. M., & Tershakovec, A. M. (2016) · Future Cardiology · doi:10.2217/fca-2015-0011 · Cited by 17
Omae, T., Nagaoka, T., Tanano, I., Kamiya, T., & Yoshida, A. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-8841 · Cited by 16
Retinopathy Progression in Type 2 Diabetes
Liew, G., Wang, J. J., & Mitchell, P. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1009236 · Cited by 16
New Recommendations for Treating Hypertension in Black Patients
Wright, J. T., Agodoa, L. Y. C., Appel, L. J., Cushman, W. C., Taylor, A. L., Obegdegbe, G. G., Osei, K., & Reed, J. W. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.159566 · Cited by 16
Zhou, T., Yan, K., Zhang, Y., Zhu, L., Liao, Y., Zheng, X., Chen, Y., Li, X., Liu, Z., & Zhang, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1000254 · Cited by 15
Tan, H., Fu, X., Chen, Y., Wang, Y., & Chen, D. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21109 · Cited by 15
Wolfrum, P., Böhm, E. W., Lorenz, K., Stoffelns, B. M., Pfeiffer, N., & Korb, C. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154508 · Cited by 17
Predicting the Future Burden of Diabetes in Alberta from 2008 to 2035
Lau, R. S., Öhinmaa, A., & Johnson, J. A. (2011) · Canadian Journal of Diabetes · doi:10.1016/s1499-2671(11)53011-4 · Cited by 17
Safety review of combination drugs for hyperlipidemia
Farnier, M. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.540237 · Cited by 15
An updated review of lipid‐modifying therapy
Simons, L. A. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50142 · Cited by 18
Effect of Fenofibrate on the Expression of Inflammatory Mediators in a Diabetic Rat Model
Yeh, P., Wang, L., Chang, S., Yang, W., Yang, C., & Yang, C.-H. (2019) · Current Eye Research · doi:10.1080/02713683.2019.1622020 · Cited by 15
Cortes-Lopez, F., Sánchez-Mendoza, A., Centurión, D., Cervantes-Pérez, L. G., Castrejón-Téllez, V., del Valle‐Mondragón, L., Soria‐Castro, E., Ramírez, V., Sánchez‐López, A., Pastelín-Hernández, G. S., et al. (2021) · PPAR Research · doi:10.1155/2021/8895376 · Cited by 16
Outcomes of Diabetic Retinopathy Post-Bariatric Surgery in Patients with Type 2 Diabetes Mellitus
Dascălu, A. M., Stoian, A. P., Popa‐Cherecheanu, A., Şerban, D., Costea, D. O., Tudosie, M. S., Stana, D., Tănăsescu, D., Sabău, A. D., Gangura, G. A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163736 · Cited by 18
Mancini, G. B. J., Hegele, R. A., & Leiter, L. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.032 · Cited by 15
Kim, I., Williams, R. H., Schutzler, S. E., Lasley, C. J., Bodenner, D., Wolfe, R. R., & Coker, R. H. (2014) · Nutrition & Metabolism · doi:10.1186/1743-7075-11-49 · Cited by 15
Significant retinopathy in young-onset type 2 vs. type 1 diabetes: a clinical observation
Song, S. H. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12789 · Cited by 15
Diabetic retinopathy clinical practice guidelines: Customized for Iranian population
Safi, S., Rajavi, Z., Javadi, M. A., Azarmina, M., Moradian, S., Entezari, M., Nourinia, R., Ahmadieh, H., Shirvani, A., Shahraz, S., et al. (2016) · Journal of Ophthalmic and Vision Research · doi:10.4103/2008-322x.194131 · Cited by 14
Ciorba, A. L., Saber, S., Abdelhamid, A. M., Keshk, N., Elnaghy, F., Elmorsy, E. A., Abu‐Khudir, R., Hamad, R. S., Abdel‐Reheim, M. A., Farrag, A. A. M., et al. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107307 · Cited by 19
Fu, D., Yu, Y., Connell, A. R., Hookham, M. B., McLeese, R. H., & Lyons, T. J. (2020) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2020.0068 · Cited by 14
Small-Molecule Modulation of PPARs for the Treatment of Prevalent Vascular Retinal Diseases
Dou, X., & Duerfeldt, A. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239251 · Cited by 14
Yao, F., Zhang, X., Yao, X., Ren, X., Xia, X., Jiang, J., & Ding, L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.788663 · Cited by 14
Paúl, S., Tayar, A., Morawiec‐Kisiel, E., Bohl, B., Großjohann, R., Hunfeld, E., Busch, M., Pfeil, J. M., Dähmcke, M., Brauckmann, T., et al. (2022) · Die Ophthalmologie · doi:10.1007/s00347-021-01556-5 · Cited by 14
Aljehani, E. A., Alhawiti, A. E., & Mohamad, R. M. A. (2023) · Cureus · doi:10.7759/cureus.42771 · Cited by 14
Chen, Y., Yu, Y., & An, J. (2024) · Nutrients · doi:10.3390/nu16091393 · Cited by 17
Oshitari, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910485 · Cited by 15
Fibrates and niacin: is there a place for them in clinical practice?
Wierzbicki, A. S., & Viljoen, A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.972365 · Cited by 15
Emerging options in the treatment of dyslipidemias: a bright future?
Florentin, M., Liberopoulos, E. N., Mikhailidis, D. P., & Elisaf, M. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.554395 · Cited by 14
Impact of estimated glomerular filtration rate on diabetic macular edema
Temkar, S., Karuppaiah, N., Takkar, B., Bhowmik, D. M., Tripathi, M., Ramakrishnan, S., Sharma, Y. R., Vohra, R., Chawla, R., & Venkatesh, P. (2017) · International Ophthalmology · doi:10.1007/s10792-017-0557-8 · Cited by 13
KEECH, A. C., & Jenkins, A. J. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000465 · Cited by 14
Blood pressure targets for hypertension in patients with type 2 diabetes
Aronow, W. S., & Shamliyan, T. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.36 · Cited by 15
Neeland, I. J., & Patel, K. V. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54835-9.00004-1 · Cited by 14
Integrative Biology of Diabetic Retinal Disease: Lessons from Diabetic Kidney Disease
Pan, W. W., Gardner, T. W., & Harder, J. L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061254 · Cited by 14
Giuseppe, G. D., Ciccarelli, G., CEFALO, C. M. A., Cinti, F., Moffa, S., Impronta, F., Capece, U., Pontecorvi, A., Giaccari, A., & Mezza, T. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.21.03405-9 · Cited by 17
Grauslund, J., Pedersen, F. N., Andersen, N., Andresen, J., Bek, T., Dinesen, S., Hajari, J. N., Heegaard, S., Højlund, K., Laugesen, C. S., et al. (2022) · Acta Ophthalmologica · doi:10.1111/aos.15264 · Cited by 14
Epidemiology of Ocular Functions and Diseases in Persons With Diabetes
Klein, R., & Klein, R. (2018) · Europe PMC (PubMed Central) · Cited by 13
Left ventricular structure and function in prediabetic adults:Relationship with insulin resistance
Sliem, H. A., & Nasr, G. M. (2011) · Journal of Cardiovascular Disease Research · doi:10.4103/0975-3583.78583 · Cited by 14
Apolipoproteins and Diabetic Retinopathy
Chait, A., & Montes, V. N. (2011) · Diabetes Care · doi:10.2337/dc10-2119 · Cited by 14
Systemic Therapies for Diabetic Retinopathy
Frank, R. N. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.08.019 · Cited by 14
Sociodemographic variables associated with risk for diabetic retinopathy
Nguyen, C. T. N., Yosef, M., Khalatbari, S. H., & Shah, A. R. (2022) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-022-00144-z · Cited by 13
The Role of Platelets in Hypoglycemia-Induced Cardiovascular Disease: A Review of the Literature
Ali, A. A. G., Niinuma, S. A., Moin, A. S. M., Atkin, S. L., & Butler, A. E. (2023) · Biomolecules · doi:10.3390/biom13020241 · Cited by 13
Update on current pharmacologic therapies for diabetic retinopathy
Muns, S. M., Villegas, V. M., Flynn, H. W., & Schwartz, S. G. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2230139 · Cited by 13
Associations between fatty acid intake and diabetic retinopathy in a Japanese population
Sasaki, M., Yuki, K., Hanyuda, A., Yamagishi, K., Motomura, K., Kurihara, T., Tomita, Y., Mori, K., Ozawa, N., Ozawa, Y., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-39734-x · Cited by 13
Discriminating early-stage diabetic retinopathy with subjective and objective perimetry
Sabeti, F., Kleef, J. P. V., Iyer, R. M., Carle, C. F., Nolan, C. J., Chia, R. H., & Maddess, T. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1333826 · Cited by 13
Varughese, M. S., Nayak, A., & Jacob, S. (2024) · Eye · doi:10.1038/s41433-024-03410-9 · Cited by 13
The metabolic syndrome and severity of diabetic retinopathy
Chen, J. J.-W., Wendel, L., Birkholz, E. S., Vallone, J. G., Coleman, A. L., Yu, F., & Mahajan, V. B. (2015) · Clinical ophthalmology · doi:10.2147/opth.s80355 · Cited by 13
Avoiding hypoglycaemia: a new target of care for elderly diabetic patients
Wong, C. (2015) · Hong Kong Medical Journal · doi:10.12809/hkmj144494 · Cited by 14
Shiraya, T., Araki, F., Ueta, T., Fukunaga, H., Totsuka, K., Arai, T., Uemura, A., Moriya, K., & Kato, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-58039-x · Cited by 16
Diabetic retinopathy in well-controlled type 2 diabetes: Role of glycaemic memory
Ducos, C., Rigo, M., Larroumet, A., Delyfer, M., Korobelnik, J.-F., Monlun, M., Foussard, N., Poupon, P., Haissaguerre, M., Blanco, L., et al. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.03.005 · Cited by 13
Кручинина, М. В., Gromov, А. А., Генералов, В. М., & Кручинин, В. Н. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030060 · Cited by 13
Imaging the eye and its relevance to diabetes care
Quinn, N. B., Jenkins, A. J., Ryan, C. D., Januszewski, A. S., Pető, T., & Brazionis, L. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13462 · Cited by 13
Novel therapies for diabetic retinopathy
Kupis, M., Samelska, K., Szaflik, J. P., & Skopiński, P. (2022) · Central European Journal of Immunology · doi:10.5114/ceji.2022.112993 · Cited by 13
Durlach, V., Durlach, A., Movesayan, I., Socquard, E., Zellner, C., Clavel, C., Nazeyrollas, P., Malloy, M. J., Pullinger, C. R., Kane, J., et al. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.07.010 · Cited by 13
Bouhanick, B., Barigou, M., Kantambadouno, J.-B., & Chamontin, B. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.02.315 · Cited by 14
Current and future management of diabetic retinopathy: a personalized evidence-based approach
Fante, R. J., Gardner, T. W., & Sundstrom, J. M. (2013) · Diabetes Management · doi:10.2217/dmt.13.50 · Cited by 13
Leveraging Nuclear Receptors as Targets for Pathological Ocular Vascular Diseases
Yao, P., Peavey, J. J., & Malek, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082889 · Cited by 13
Proliferative Diabetic Retinopathy
Silva, P. A. S., Cavallerano, J. D., Sun, J. K., Blodi, B. A., Davis, M. D., Aiello, L. M., & Aiello, L. P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00048-5 · Cited by 13
Pek, S. L. T., Sum, C. F., Yeoh, L. Y., Lee, S. B. M., Tang, W. E., Lim, S. C., & Subramaniam, T. (2017) · Metabolism · doi:10.1016/j.metabol.2017.03.016 · Cited by 13
Reduction in Risk of Progression of Diabetic Retinopathy
Klein, R. (2010) · New England Journal of Medicine · doi:10.1056/nejme1005667 · Cited by 13
Koh, K. K., Oh, P. C., Sakuma, I., Lee, Y., Han, S. H., & Shin, E. K. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.038 · Cited by 11
Yusufu, M., Zhang, X., Sun, X., Raat, H., & Wang, N. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107834 · Cited by 12
Toma, C., Ferdeghini, D., Pour, M. M. O., Venkatesan, S., Cillà, S. D., & Grossini, E. (2026) · Antioxidants · doi:10.3390/antiox15040425 · Cited by 13
Hermans, M. P., Bouénizabila, E., Amoussou-Guenou, K. D., Gninkoun, C. J., Ahn, S. A., & Rousseau, M. F. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102613 · Cited by 12
Sabeti, F., Rai, B. B., Kleef, J. P. V., Rohan, E. M. F., Carle, C. F., Barry, R., Essex, R. W., Nolan, C. J., & Maddess, T. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287319 · Cited by 12
Hartnett, M. E., Fickweiler, W., Adamis, A. P., Brownlee, M., Das, A., Duh, E. J., Feener, E. P., King, G. L., Kowluru, R. A., Luhmann, U. F. O., et al. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2024.100521 · Cited by 13
Zhou, X., Hou, G., Wang, X., Peng, Z., Yin, X., Yang, J., Wang, S., He, Y., Wang, Y., Sui, J., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02535-1 · Cited by 12
Hyperlipidaemia and cardiovascular disease
Saha, S. A., & Arora, R. R. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834701c3 · Cited by 12
Macular oedema as manifestation of diabetic retinopathy
Bikbov, M. M., Fayzrakhmanov, R. R., Zainullin, R. M., Zaynetdinov, A. F., Риксович, Г. Т., & Римович, К. М. (2017) · Diabetes Mellitus · doi:10.14341/dm8328 · Cited by 13
Lin, Y.-C., Chen, Y.-C., Horng, J., & Chen, J.-M. (2020) · Medicina · doi:10.3390/medicina56080385 · Cited by 12
Metadata
- Authors
- The ACCORD Study Group and ACCORD Eye Study Group
- Corresponding author
- The ACCORD Study Group and ACCORD Eye Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-07-15
- Volume
- 363
- Issue
- 3
- Pages
- 233-244
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4026164
- OpenAlex
- W2219384223
- Semantic Scholar
- 9a607a3bfd9432a917f703d573fdaa1052647711
- Cited by
- 1,311
- References
- 36
- Citations by year
- 2026: 54 · 2025: 60 · 2024: 66 · 2023: 86 · 2022: 73 · 2021: 94 · 2020: 96 · 2019: 57 · 2018: 78 · 2017: 87 · 2016: 82 · 2015: 84 · 2014: 74 · 2013: 81 · 2012: 93
- FWCI
- 111.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Regeneron Pharmaceuticals
- Massachusetts Medical Society
- Omron Healthcare
- Bayer HealthCare
- Daiichi-Sankyo
- Novo Nordisk
- Servier
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, Z99 EY999999, n01hc95178-28-0-1, n01hc95179-25-0-0)
- Centers for Disease Control and Prevention
- National Institute on Aging
- National Heart, Lung, and Blood Institute (N01- HC-95181, R01HL073030, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, IAAY1-HC-1010, IAA #Y1-HC-9035, N01 HC095180, Y01 HC009035, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- National Eye Institute (ZIAEY000410)
- National Institute of Diabetes and Digestive and Kidney Diseases
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- diabetic retinopathy, retinopathy progression, type 2 diabetes, tight glycemic control, HbA1c, fenofibrate, simvastatin, dyslipidemia, blood pressure control, laser photocoagulation, vitrectomy, cardiovascular risk reduction, combination therapy, Early Treatment Diabetic Retinopathy Study
- MeSH terms
- Antihypertensive Agents, Hypolipidemic Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Drug Therapy, Combination, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hyperglycemia, Hypertension, Hypoglycemic Agents, Cholesterol, LDL, Male, Middle Aged, Fenofibrate, Disease Progression, Simvastatin, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
